eligibility_summary
Eligible: Adults (≥18) with Ph−/BCR‑ABL−, CD22+ ALL/lymphoblastic lymphoma in relapse or refractory after ≥3 intensive cycles, ECOG 0–2, adequate renal/hepatic/pancreatic/cardiac function (EF>60%, PASP≤50), HIV/HBV/HCV negative, consent. Exclude: CD22−, mixed lineage, other malignancy/serious comorbidity, severe allergy to study drugs, significant liver or active cardiac disease, psych issues, pregnancy/lactation, unable to consent, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm phase 1/2 trial in adults with relapsed/refractory Philadelphia chromosome–negative ALL or B‑cell lymphoma testing: • Chidamide (tucidinostat): benzamide-class selective HDAC1/2/3/10 inhibitor (small molecule) to modulate epigenetics and promote apoptosis/sensitization. • Venetoclax: BCL‑2 inhibitor (small molecule) to trigger mitochondrial apoptosis in B‑cell blasts. • Inotuzumab ozogamicin: anti‑CD22 antibody–drug conjugate delivering calicheamicin to induce DNA double‑strand breaks. Responders bridge to alloHSCT, post‑HSCT chidamide maintenance for 1 year. Targets/pathways: CD22+ B‑lineage leukemic/lymphoma cells, BCL‑2 survival pathway, HDAC-mediated epigenetic regulation, calicheamicin-induced DNA damage.